BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
Federal Trade Commission
Cantor Fitzgerald
Cerilliant
Citi
Deloitte
Fuji
US Department of Justice
Colorcon
Baxter

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021174

« Back to Dashboard

NDA 021174 describes MYLOTARG, which is a drug marketed by Wyeth Pharms Inc and is included in one NDA. Additional details are available on the MYLOTARG profile page.

The generic ingredient in MYLOTARG is gemtuzumab ozogamicin. Additional details are available on the gemtuzumab ozogamicin profile page.
Summary for 021174
Tradename:MYLOTARG
Applicant:Wyeth Pharms Inc
Ingredient:gemtuzumab ozogamicin
Patents:0

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;INJECTIONStrength5MG/VIAL
Approval Date:May 17, 2000TE:RLD:No

Expired US Patents for NDA 021174

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Wyeth Pharms Inc MYLOTARG gemtuzumab ozogamicin INJECTABLE;INJECTION 021174-001 May 17, 2000 ➤ Subscribe ➤ Subscribe
Wyeth Pharms Inc MYLOTARG gemtuzumab ozogamicin INJECTABLE;INJECTION 021174-001 May 17, 2000 ➤ Subscribe ➤ Subscribe
Wyeth Pharms Inc MYLOTARG gemtuzumab ozogamicin INJECTABLE;INJECTION 021174-001 May 17, 2000 ➤ Subscribe ➤ Subscribe
Wyeth Pharms Inc MYLOTARG gemtuzumab ozogamicin INJECTABLE;INJECTION 021174-001 May 17, 2000 ➤ Subscribe ➤ Subscribe
Wyeth Pharms Inc MYLOTARG gemtuzumab ozogamicin INJECTABLE;INJECTION 021174-001 May 17, 2000 ➤ Subscribe ➤ Subscribe
Wyeth Pharms Inc MYLOTARG gemtuzumab ozogamicin INJECTABLE;INJECTION 021174-001 May 17, 2000 ➤ Subscribe ➤ Subscribe
Wyeth Pharms Inc MYLOTARG gemtuzumab ozogamicin INJECTABLE;INJECTION 021174-001 May 17, 2000 ➤ Subscribe ➤ Subscribe
Wyeth Pharms Inc MYLOTARG gemtuzumab ozogamicin INJECTABLE;INJECTION 021174-001 May 17, 2000 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Teva
Baxter
Federal Trade Commission
Queensland Health
Mallinckrodt
US Army
Dow
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot